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ABSTRACT. Certain glutathione S-transferase (GST) isoenzymes detoxify the cell from xenobiotics, thus becoming inhibition targets when 
overexpressed in various tumours leading to MDR. We developed a combinatorial strategy aiming at designing peptide inhibitors against the 
hGSTP1-1 isoenzyme involved in MDR. We employed a combinatorial peptide library featuring engineered E. coli cells harboring a plasmid 
able to express a fusion protein containing random 12peptides which were inserted into the active loop of thioredoxin, which itself was 
inserted into the dispensable region of the flagellin gene. After five selection rounds, clones were screened for hGSTP1-1 binding and those 
with the strongest signal were selected and sequenced. Sequence alignments showed a core binding sequence which, along with selected 
peptide fragments, were synthesized using the solid phase methodology and Fmoc/tBu chemistry on 2-chlorotrityl chloride solid support. The 
four peptides were studied for their inhibition potency against hGSTP1-1 allozymes A, B and C. 
INTRODUCTION. Glutathione S-transferases (GSTs, EC 2.5.1.18) are 
a family of isoenzymes that differ in their tissue-specificity expression 
and distribution. They catalyse the conjugation of glutathione (GSH) to 
a variety of hydrophobic endogenous and exogenous substrates, 
rendering them hydrophilicity and facilitating their metabolic 
processing and eventual secretion from the cell [1]. Cancer cells may 
acquire resistance by overexpressing GST activities, hampering the 
effectiveness of certain chemotherapeutic drugs [2,3]. Several synthetic 
compounds exhibiting inhibition potency against GSTs have been 
proposed as strategies to overcoming MDR attributed to GST 
overexpression [5-8]. We report on the design, synthesis and 
enzymological evaluation of peptides as inhibitors for hGSTP1-1 
allozymes A,B,C. 
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RESULTS/CONCLUSIONS. Peptide design (Figure 1) was 
accomplished through an iterative binding cycle called panning 
using a bacterial surface peptide display library (FliTrx) with an 
estimated diversity of 1.77X108 possible peptide combinations 
using hGSTP1-1 as the target. The bacterial peptide display 
library was comprised of E. coli cells harbouring a plasmid 
(pFlitrx, Figure 2) engineered to express a fusion protein 
containing random dodecapeptides that were inserted into the 
active loop of thioredoxin, which itself was inserted into a 
dispensable of flagellin, the major constituent of flagellar 
filaments. When the fusion protein becomes an integral part of 
the flagellar filaments on the bacterial cell surface, the 
dodecapeptides become available to interact with target 
proteins.  After 5 continuous selection rounds, different clones 
were screened for hGSTP1-1 binding  by dot blot (Figure 3) and 
the clones exhibiting the strongest signal were selected and 
their sequence determined by nucleotide sequencing. Sequence 
alignments showed a core binding sequence (PATAISLGGG) 
which, along with selected peptide fragments (PATAI, SLGGG, 
AISL), were synthesized using the solid phase methodology and 
Fmoc/tBu chemistry on 2-chlorotrityl chloride solid support.  
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Allozyme Substrate 
Vmax 
(μmol·min-1·mL-1) 
kcat 
(min-1) 
Km 
(mM) 
kcat/Km 
(min-1·mM-1) 
hGSTP1A 
GSH 0.0284 ±0.0005 
1051.85 
±18.52 
0.1277 
±0.0065 
8236.88 
±594.55 
CDNB 0.0688 ±0.0023 
2991.30 
±100,00 
1.3205 
±0.0844 
2265.28 
±235.56 
hGSTP1B 
GSH 0.0165 ±0.0003 
458.33 
±8.34 
0.1489 
±0.0081 
3078.11 
±236.31 
CDNB 0.0321 ±0.0005 
891.67 
±13.89 
1.1627 
±0.0488 
766.90 
±46.06 
hGSTP1C 
GSH 0.0140 ±0.0003 
205.88 
±4.41 
0.1275 
±0.0071 
1614.75 
±131.84 
CDNB 0.0233 ±0.0003 
456.86 
±5.89 
1.0692 
±0.0366 
427.29 
±20.85 
 
Peptide 
 
Inhibition of hGSTP1-1 (%, compared in the absence of inhibitor) 
 
A B C 
TH10 : 
Pro-Ala-Thr-Ala-Ile- 
Ser-Leu-Gly-Gly-Gly 
 
32.2 
 
58.0 
 
25.4 
TH5N : 
Pro-Ala-Thr-Ala-Ile 
29.2 46.6 14.3 
TH5C : 
Ser-Leu-Gly-Gly-Gly 
34.2 42.2 18.7 
TH4 : 
Ala-Ile-Ser-Leu 
15.0 30.6 16.8 
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Table 1. Kinetic constants for hGSTP1 allozymes A, B & C.  
Table 2. Inhibition of hGSTP1 allozymes by peptides designed on the 
basis of results from the E. coli  displayed combinatorial library.  
Figure 1. Schematic representation of the strategy 
employed for the combinatorial design and 
characterization of peptide inhibitors towards 
hGSTA1-1.  
The purified allozymes were subjected to kinetic study and 
inhibition tests with the desiged peptides.  
 It appears that the mutations of the allozymes hGSTP1*A 
(Ile104/Ala113), hGSTP1*B (Val104/Ala113) & hGSTP1*C (Val104/Val113) 
have small influence on the binding affinity between substrate & 
enzyme (Table 1, Km values), but result in significant changes of 
the catalytic reaction (Table 1, kcat values) and, hence, the overall 
catalytic efficiency (Table 1, kcat /Km values). 
 Furthermore, these mutations influence the inhibitory ability 
of the designed peptides. TH10 is the most effective inhibitor 
(Table 2), with the shorter counterparts showing varied inhibitory 
potency depending on the allozyme.  
 Rationalization of the above results requires the engagement 
of molecular modeling and dynamic approaches.   
→ 
